Hutchmed (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates in the commercial stage, with its first three medicines marketed in China and one approved in multiple international markets, including the US, Europe, and Japan. Hutchmed aims to bring drug candidates from in-house discovery to patients globally.
